These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
195 related items for PubMed ID: 21253585
1. Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. Brust JC, Lygizos M, Chaiyachati K, Scott M, van der Merwe TL, Moll AP, Li X, Loveday M, Bamber SA, Lalloo UG, Friedland GH, Shah NS, Gandhi NR. PLoS One; 2011 Jan 06; 6(1):e15841. PubMed ID: 21253585 [Abstract] [Full Text] [Related]
5. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis-Human Immunodeficiency Virus Coinfection in South Africa. Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Clin Infect Dis; 2018 Apr 03; 66(8):1246-1253. PubMed ID: 29293906 [Abstract] [Full Text] [Related]
9. Drug-resistant tuberculosis among HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Hom JK, Wang B, Chetty S, Giddy J, Mazibuko M, Allen J, Walensky RP, Losina E, Freedberg KA, Bassett IV. PLoS One; 2012 Apr 03; 7(8):e43281. PubMed ID: 22912845 [Abstract] [Full Text] [Related]
10. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, Seung KJ. PLoS One; 2012 Apr 03; 7(10):e46943. PubMed ID: 23115633 [Abstract] [Full Text] [Related]
14. Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa. Mokhele I, Jinga N, Berhanu R, Dlamini T, Long L, Evans D. BMC Pregnancy Childbirth; 2021 Jun 28; 21(1):453. PubMed ID: 34182944 [Abstract] [Full Text] [Related]
17. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, Allana S, Campbell A, Nelson KN, Master I, Brust JCM. J Acquir Immune Defic Syndr; 2020 Jan 01; 83(1):47-55. PubMed ID: 31809360 [Abstract] [Full Text] [Related]
18. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement. Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, Khaparde SD. PLoS One; 2018 Jan 01; 13(4):e0193903. PubMed ID: 29641576 [Abstract] [Full Text] [Related]
19. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V. Ann Intern Med; 2006 May 02; 144(9):650-9. PubMed ID: 16670134 [Abstract] [Full Text] [Related]